Vertex and AbCellera are collaborating to advance T cell therapies (TCEs) for autoimmune diseases.
2 reports, 2 independent
Updated Aug 14
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vertex and AbCellera are collaborating to advance T cell therapies (TCEs) for autoimmune diseases.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AbCellera announced that its Phase II clinical trial data exceeded expectations for blockbuster potential on August 11, 2026.Sub-event
Collaboration between Vertex and AbCellera advances T cell therapies for autoimmune diseases.1 source